Clinical Case of Artesunate Resistant *Plasmodium falciparum* Malaria in Kolkata: A First Report

Bhattacharyya N1, Mukherjee H2, Bose D3, Roy S4, Das S4, Tripathy S4 and Hati AK5*

1Division of Virology and Medical Entomology, Calcutta School of Tropical Medicine, Kolkata, India
2Medical Entomology, Calcutta School of Tropical Medicine, Kolkata, India
3Department of Pathology Calcutta Medical College, Kolkata, India
4Immunology and Microbiology Laboratory, Department of Human Physiology with Community Health, Vidyasagar University, Midnapore, India
5Department of Medical Entomology, Division of Parasitology, Calcutta School of Tropical Medicine, Kolkata, India

**Abstract**

The World Health Organization has urged to set up artemisinin-based combination therapy (artemisinin and effective antimalarial drug) and gradually pull out oral artemisinin mono-therapies from the making of prescription due to their high recrudescence rates and to reduce the risk of drug resistance. Prescription practices by physicians and the availability of oral artemisinin monotherapies with pharmacists directly affect the pattern of their use as a result the first clinical case report of only artesunate resistant *P. falciparum* malaria has been found from Kolkata. A significant failure rate of artesunate and SP (9.5%) has recently been observed in the district Jalpaiguri, West Bengal, though no specific mutation has been observed in pATPase6 gene. In view of the above findings to get a clear picture of artemisinin resistance in *P. falciparum* a thorough study is required involving *in vivo*, *in vitro* and molecular procedures in this vulnerable area.

**Keywords:** Malaria; *Plasmodium falciparum*; Artisunate; ACT; Drug resistant

**Introduction**

The World Health Organization (WHO) recommends the use of artemisinin derivatives only in combination with efficient partner drugs against *Plasmodium falciparum* malaria to make sure high cure rates and postponement resistance. Artemisinins produce rapid therapeutic response, reduce gametocyte carriage, and are well tolerated by patients [1]. The five formulations of Artisinin Combination Therapy (ACT) are artemether-lumefantrine, artesunate-mefloquine, artesunate-amodiaquine, artesunate-sulphadoxine-pyrimethamine and dihydroartemisinin-piperaquine [2]. The ACT was introduced by the National Vector Borne Disease Control Programme (NVBDCP) as the first-line treatment of falciparum malaria in 117 districts which represented more than 90% of the reported *P. falciparum* cases [3]. Presently all formulations of ACT recommended by WHO, except dihydroartemisinin-piperaquine, are registered with the Drug Controller General of India to treat the patient as well as to overcome the resistant property of *P. falciparum*.

Now, the success of a new treatment policy is dependent on the adherence of health providers to the guideline and the compliance of patients with the recommended treatment. Equally, information on current provider and patient practices is needed to inform and improve future treatment policy [4]. But our recent report suggests the inappropriate treatment practices continue in spite of the availability of evidenced-based guidelines.

**Case Report**

This report stated an *in vivo* artesunate resistant *Plasmodium falciparum* case in Kolkata, capital of West Bengal (Figure 1). A female patient (SL), 57 years of age, was a resident of central Kolkata, West Bengal, India. The patient was suffering from fever with chill and rigor on alternate days from 20th October, 2012. She examined her blood on 26.10.2012 following the advice of her local physician for malaria parasite and dual antigen (PF/PV HRP2 / LDH) tests in the Gautam Laboratories, 9A, K K Tagore street, Kolkata 700007. Both thick (Giemsas stained) and thin (Leishman stained) films of the patient were observed. Malaria antigens were tested applying malaria antigen...
Microscopic observation suggested the presence of *P. falciparum* rings in her blood and *P. falciparum* antigen was also detected. Then she was treated by her physician with artesunate (Falcigo) injection alone, 120 mg i.m. on the first day (26.10.12) followed by 60mg i.m. daily for the next four days. She became a febrile on and from 28.10.2012. Her blood was tested on 6.11.2012, when no malaria parasite was found.

But, on 19th November, 2012, the patient was attacked by fever. Again her blood was examined on 20.11.12. *P. falciparum* rings were present and falciparum antigen was also found to be positive. In this time the membrane surface protein test suggests that the patient was recurrence of infection and not the re-infection. This time she was treated with six tablets of artemether 80 mg and lumefantrine 480 mg (Lumether forte DT) from 20.11.2012 administered orally at 0, 6, 24, 36, 48 and 60 hr. She became a febrile from 21.11.2012 and her blood was examined on 21.11.2012, 22.11.2012, 23.11.2012, 29.11.2012, 13.12.2012 and 25.12.2012 and in all the occasions malaria parasite was not found in her blood. She had no history of movement to neighboring countries in recent years.

These results demonstrated that the patient was clinically resistant to artesunate. It was a late treatment failure case. However, the combined therapy (artemether and lumefantrine) was effective in her case, as though the exact protocol was not maintained, in her blood no malaria parasite was found on day 7, 21 and 36, after completion of her treatment with artemether and lumefantrine combined therapy.

**Discussion**

This is the first clinical case report of only artesunate resistant *P. falciparum* malaria from Kolkata. Though the present national drug policy is ACT (artemisinin and SP) [5] that has not been followed in this particular case. It is possible that such practices are continuing even with ACT. A significant failure rate of artesunate and SP (9.5%) has recently been observed in the district Jalpaiguri, West Bengal, though no specific mutation has been observed in *pfATPase6* gene [6]. In view of the above findings to get a clear picture of artemisinin resistance in *P. falciparum* a thorough study is required involving in vivo, in vitro and molecular procedures in this vulnerable area. Rationality of inclusion of SP in ACT also raises a serious question as among isolates from Kolkata most common mutations in *dhfr* gene (responsible for pyrimethamine resistance) are at positions 108 and 51. The mutation is also found in *C59R* [7]. Again, in Kolkata 36.67% of isolates contains quadruple *dhps AGEAT* mutation (436+437+540+613), responsible for sulphadoxine resistance [8]. This case suggests that combination therapy effective as well as artesunate and lumefantrine in such cases is more practicable and efficacious than any other combination.

**References**